Latest debt-to-equity ratio
SAB Biotherapeutics Debt-to-equity ratio
Direct answer
SAB Biotherapeutics's debt-to-equity ratio is 2.39%.
The verified market snapshot reports 2.39%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked September 27, 2026.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 2.39%
Explore related company data
View SAB Biotherapeutics's market capitalizationView SAB Biotherapeutics's p/e ratioView SAB Biotherapeutics's price-to-book ratioView SAB Biotherapeutics's return on equityView SAB Biotherapeutics's 52-week price rangeView SAB Biotherapeutics's profit marginView all SAB Biotherapeutics key metricsReturn to SAB Biotherapeutics profile